Search company, investor...

Theraclone Sciences


Series C | Alive

Total Raised


Last Raised

$3.08M | 8 yrs ago

About Theraclone Sciences

Theraclone Sciences, formerly Spaltudaq, is a biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The companys technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human subjects. Human monoclonal antibodies can be rapidly isolated using the ISTAR discovery platform and scaled for industrial production. Such human antibody drug candidates may be uniquely safe and relevant to combating disease across broad patient populations.

Headquarters Location

1124 Columbia Street Suite 300

Seattle, Washington, 98104,

United States


Missing: Theraclone Sciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Theraclone Sciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Theraclone Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Theraclone Sciences is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

1,568 items

Theraclone Sciences Patents

Theraclone Sciences has filed 36 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, HIV/AIDS, Clusters of differentiation, Immune system, Immunology


Application Date


Grant Date



Related Topics

Monoclonal antibodies, HIV/AIDS, Clusters of differentiation, Immune system, Immunology



Latest Theraclone Sciences News

Seattle biotech OncoResponse raises $40.6M to create antibody-based treatments for cancer

Mar 31, 2021

Seattle biotech OncoResponse raises $40.6M to create antibody-based treatments for cancer March 31, 2021 at 11:46 am Share Clifford Stocks. (OncoResponse Photo) New funding: OncoResponse raised a $40.6M Series C investment round as it continues to develop antibodies that fight cancer. The science: The company examined the immune systems of cancer patients who responded unusually well to immunotherapy treatments. It aims to harness antibodies from those immune systems to make new immunotherapy treatments for patients whose systems do not respond well to existing options. Leadership: The company is led by CEO and founder Clifford Stocks , who previously led Theraclone Sciences and was a longtime exec at ICOS Corporation, which was acquired by Lilly for $2.3 billion in 2007. Investors: Members of the Magnetar Group led the round, which included participation from Yonjin Venture, Bering Capital, RiverVest Venture Partners, Qatar Investment Authority (QIA), Redmile Group, 3B Future Health Fund (Helsinn Investment Fund), Canaan Partners and ARCH Venture Partners. The company has now raised nearly $110 million since it was launched by The University of Texas MD Anderson Cancer Center and the now-closed Theraclone Sciences in 2015. Seattle biotech activity: This week another Seattle biotech startup also raised funding, as Outpace Bio landed $30 million . Seattle-based Rodeo Therapeutics, meanwhile, announced its acquisition by Amgen. Taylor Soper is GeekWire's managing editor, responsible for coordinating the newsroom, planning coverage, and editing stories. A native of Portland, Ore., and graduate of the University of Washington, he was previously a GeekWire staff reporter, covering beats including startups and sports technology. Follow him @taylor_soper and email .

Theraclone Sciences Frequently Asked Questions (FAQ)

  • Where is Theraclone Sciences's headquarters?

    Theraclone Sciences's headquarters is located at 1124 Columbia Street, Seattle.

  • What is Theraclone Sciences's latest funding round?

    Theraclone Sciences's latest funding round is Series C.

  • How much did Theraclone Sciences raise?

    Theraclone Sciences raised a total of $63.75M.

  • Who are the investors of Theraclone Sciences?

    Investors of Theraclone Sciences include Canaan Partners, ARCH Venture Partners, MPM Capital, Amgen Ventures, Zenyaku Kogyo and 10 more.

  • Who are Theraclone Sciences's competitors?

    Competitors of Theraclone Sciences include ISA Pharmaceuticals, Symphogen, CoImmune, VentiRx Pharmaceuticals, Activate Immunotherapy and 12 more.

Compare Theraclone Sciences to Competitors

ISA Pharmaceuticals

ISA Pharmaceuticals develops treatments for various cancers and infectious diseases. It focuses on the development of synthetic peptide vaccines that boost the immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. The company was founded in 2004 and is based in Oestgeest, Netherlands.

Mimetogen Pharmaceuticals

Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.

Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Anza Therapeutics

Anza Therapeutics is developing active immunotherapies for the treatment of infectious diseases and cancer. Anza's therapeutic agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease being treated.


ImmuRx is focused on cancer and chronic infectious disease by stimulating both the innate and adaptive halves of the immune system. Per the company, ImmuRx has demonstrated significantly greater immune responses and greater therapeutic benefit than most competing adjuvants in a wide variety of disease indications.


BioMs develops biologics for autoimmune diseases with a special emphasis on multiple sclerosis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.